Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Davide Pastorelli, Fable Zustovich, Giovanni Faggioni, Stefania Zovato, Martin Donach, Ornella Nicoletto, Miriam Farina, Lara Furini, Renato Ceravolo, Paolo Carli, Giuseppe Lombardi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalAnti-Cancer Drugs
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Renal Cell Carcinoma
Interferons
Therapeutics
Guidelines
sunitinib
Bevacizumab

Keywords

  • Bevacizumab
  • Interferon
  • Renal cancer
  • Sunitinib
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma. / Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; Zovato, Stefania; Donach, Martin; Nicoletto, Ornella; Farina, Miriam; Furini, Lara; Ceravolo, Renato; Carli, Paolo; Lombardi, Giuseppe.

In: Anti-Cancer Drugs, Vol. 21, No. 2, 02.2010, p. 210-213.

Research output: Contribution to journalArticle

Pastorelli, Davide ; Zustovich, Fable ; Faggioni, Giovanni ; Zovato, Stefania ; Donach, Martin ; Nicoletto, Ornella ; Farina, Miriam ; Furini, Lara ; Ceravolo, Renato ; Carli, Paolo ; Lombardi, Giuseppe. / Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma. In: Anti-Cancer Drugs. 2010 ; Vol. 21, No. 2. pp. 210-213.
@article{55dfbc26fe4143748bd702c94d2c0949,
title = "Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma",
abstract = "In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.",
keywords = "Bevacizumab, Interferon, Renal cancer, Sunitinib, Targeted therapy",
author = "Davide Pastorelli and Fable Zustovich and Giovanni Faggioni and Stefania Zovato and Martin Donach and Ornella Nicoletto and Miriam Farina and Lara Furini and Renato Ceravolo and Paolo Carli and Giuseppe Lombardi",
year = "2010",
month = "2",
doi = "10.1097/CAD.0b013e3283340d1f",
language = "English",
volume = "21",
pages = "210--213",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

AU - Pastorelli, Davide

AU - Zustovich, Fable

AU - Faggioni, Giovanni

AU - Zovato, Stefania

AU - Donach, Martin

AU - Nicoletto, Ornella

AU - Farina, Miriam

AU - Furini, Lara

AU - Ceravolo, Renato

AU - Carli, Paolo

AU - Lombardi, Giuseppe

PY - 2010/2

Y1 - 2010/2

N2 - In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

AB - In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

KW - Bevacizumab

KW - Interferon

KW - Renal cancer

KW - Sunitinib

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=76149119094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149119094&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3283340d1f

DO - 10.1097/CAD.0b013e3283340d1f

M3 - Article

C2 - 19952729

AN - SCOPUS:76149119094

VL - 21

SP - 210

EP - 213

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -